Abstract
Introduction and Aim: We report the 2-year efficacy and tolerability of intravesical botulinum A toxin (BoNT/A) injections in patients with painful bladder syndrome (PBS) associated with increased urinary frequency refractory to conventional treatments. Materials and Methods: Thirteen women were prospectively included in the study. The preliminary assessment included voiding diary, urodynamics, urinary tract ultrasound and the visual analog scale (VAS) for pain quantification. All patients received multiple injections of 200 U commercially available BoNT/A diluted in 20 ml 0.9% NaCl, under cystoscopic guidance. Clinical evaluation, urodynamics, urinary tract ultrasound and VAS were repeated at least two times per year throughout the follow-up. Results: A total of 58 injections were administered with a mean of 4.8 ± 0.8 injections per patient. The mean interval between two consecutive injections was 5.25 ± 0.75 months. At 1 and 4 mo follow up ten patients reported a subjective improvement. Mean VAS scores, mean daytime and night-time urinary frequency decreased significantly. Nine patients at 1 month and seven at the 4-month check-up complained of dysuria. The three non-responders to the first intravesical treatment session underwent another three months later with satisfactory results. At 1 and 2 years follow up the beneficial effects persisted in all patients. We did not observe any systemic side effects during the observation time. Conclusions: Intravesically injected BoNT/A is effective and safe in the medium-term management of patients with PBS. As the beneficial effect decreased progressively within a few months after treatment, repeat injections of the neurotoxin were needed over time.
Keywords: Botulinum A toxin, pain, painful bladder syndrome
Current Drug Delivery
Title: Two -Year Efficacy and Safety of Botulinum a Toxin Intravesical Injections in Patients Affected by Refractory Painful Bladder Syndrome
Volume: 7 Issue: 1
Author(s): Antonella Giannantoni, Ettore Mearini, Michele Del Zingaro, Silvia Proietti and Massimo Porena
Affiliation:
Keywords: Botulinum A toxin, pain, painful bladder syndrome
Abstract: Introduction and Aim: We report the 2-year efficacy and tolerability of intravesical botulinum A toxin (BoNT/A) injections in patients with painful bladder syndrome (PBS) associated with increased urinary frequency refractory to conventional treatments. Materials and Methods: Thirteen women were prospectively included in the study. The preliminary assessment included voiding diary, urodynamics, urinary tract ultrasound and the visual analog scale (VAS) for pain quantification. All patients received multiple injections of 200 U commercially available BoNT/A diluted in 20 ml 0.9% NaCl, under cystoscopic guidance. Clinical evaluation, urodynamics, urinary tract ultrasound and VAS were repeated at least two times per year throughout the follow-up. Results: A total of 58 injections were administered with a mean of 4.8 ± 0.8 injections per patient. The mean interval between two consecutive injections was 5.25 ± 0.75 months. At 1 and 4 mo follow up ten patients reported a subjective improvement. Mean VAS scores, mean daytime and night-time urinary frequency decreased significantly. Nine patients at 1 month and seven at the 4-month check-up complained of dysuria. The three non-responders to the first intravesical treatment session underwent another three months later with satisfactory results. At 1 and 2 years follow up the beneficial effects persisted in all patients. We did not observe any systemic side effects during the observation time. Conclusions: Intravesically injected BoNT/A is effective and safe in the medium-term management of patients with PBS. As the beneficial effect decreased progressively within a few months after treatment, repeat injections of the neurotoxin were needed over time.
Export Options
About this article
Cite this article as:
Giannantoni Antonella, Mearini Ettore, Zingaro Del Michele, Proietti Silvia and Porena Massimo, Two -Year Efficacy and Safety of Botulinum a Toxin Intravesical Injections in Patients Affected by Refractory Painful Bladder Syndrome, Current Drug Delivery 2010; 7 (1) . https://dx.doi.org/10.2174/156720110790396463
DOI https://dx.doi.org/10.2174/156720110790396463 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Getting in Sync: A New Ready-to-use Biofield Resonance Device (Vita Chip) Reduces Chronic Pain and Increases Wellbeing
Neuroscience and Biomedical Engineering (Discontinued) Selective Neuronal Nitric Oxide Synthase Inhibitors
Current Topics in Medicinal Chemistry PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Molecule of the Month
Current Topics in Medicinal Chemistry Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry Risks Associated with Vortioxetine in the Established Therapeutic Indication
Current Neuropharmacology COVID-19 Treatment Success After Repeat Courses of Azithromycin: A Report of Three Cases
Infectious Disorders - Drug Targets Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: From Vascular Spasm to Cortical Spreading Depolarizations
Current Neurovascular Research Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets Tauopathies – Focus on Changes at the Neurovascular Unit
Current Alzheimer Research Enhancement of Delayed Audiovisual Response in Parkinson’s Disease: A Comparison with Normal Aged Controls
Neuroscience and Biomedical Engineering (Discontinued) Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Therapeutic Potential of Metabotropic GABA (GABAB) Receptors and their Effector Ion Channels
Central Nervous System Agents in Medicinal Chemistry Methods for Evaluating Sensory, Affective and Cognitive Disorders in Neuropathic Rodents
Current Neuropharmacology